BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, Gunderson LL, Goldman B, Martenson JA, Jessup JM, Stemmermann GN, Blanke CD, Macdonald JS. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-33. [PMID: 22585691 DOI: 10.1200/JCO.2011.36.7136] [Cited by in Crossref: 466] [Cited by in F6Publishing: 229] [Article Influence: 51.8] [Reference Citation Analysis]
Number Citing Articles
1 Wei J, Yao T, Wang Y, Li L, Pan C, Zhang N. Prognostic analysis of stage III gastric cancer after curative surgery according to the newest TNM classification. Clin Transl Oncol 2019;21:232-8. [PMID: 29968135 DOI: 10.1007/s12094-018-1913-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
2 Pang X, Wei W, Leng W, Chen Q, Xia H, Chen L, Li R. Radiotherapy for gastric cancer: a systematic review and meta-analysis. Tumour Biol. 2014;35:387-396. [PMID: 23929390 DOI: 10.1007/s13277-013-1054-y] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
3 Blumenthaler AN, Newhook TE, Ikoma N, Estrella JS, Blum Murphy M, Das P, Minsky BD, Ajani JA, Mansfield PF, Badgwell BD. Concurrent lymphovascular and perineural invasion after preoperative therapy for gastric adenocarcinoma is associated with decreased survival. J Surg Oncol 2021;123:911-22. [PMID: 33400838 DOI: 10.1002/jso.26367] [Reference Citation Analysis]
4 Xu XW, Yang XM, Zhao WJ, Zhou L, Li DC, Zheng YH. DNM1L, a key prognostic predictor for gastric adenocarcinoma, is involved in cell proliferation, invasion, and apoptosis. Oncol Lett 2018;16:3635-41. [PMID: 30127972 DOI: 10.3892/ol.2018.9138] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
5 Ohri N, Garg MK, Aparo S, Kaubisch A, Tome W, Kennedy TJ, Kalnicki S, Guha C. Who benefits from adjuvant radiation therapy for gastric cancer? A meta-analysis. Int J Radiat Oncol Biol Phys. 2013;86:330-335. [PMID: 23523184 DOI: 10.1016/j.ijrobp.2013.02.008] [Cited by in Crossref: 36] [Cited by in F6Publishing: 26] [Article Influence: 4.5] [Reference Citation Analysis]
6 Sun KK, Wang QH, Wu YY. Challenges surrounding postoperative adjuvant chemotherapy for T2N0 gastric cancer. Oncol Lett 2020;20:126. [PMID: 32934695 DOI: 10.3892/ol.2020.11985] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 Aznab M, Beiki O, Pia KE, Setayeshi K, Hesami MA, Vrae H. Evaluation the Survival of Patients with Gastric Cancer Treated with Adjuvant or Palliative Chemotherapy. J Gastrointest Cancer 2017;48:31-7. [PMID: 27543101 DOI: 10.1007/s12029-016-9868-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
8 Seshadri RA, Glehen O. The Role of Hyperthermic Intraperitoneal Chemotherapy in Gastric Cancer. Indian J Surg Oncol 2016;7:198-207. [PMID: 27065710 DOI: 10.1007/s13193-016-0502-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
9 Rucker AJ, Raman V, Jawitz OK, Voigt SL, Harpole DH, D'Amico TA, Tong BC. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma. Ann Surg 2020. [PMID: 32209899 DOI: 10.1097/SLA.0000000000003886] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
10 Chen X, Eads JR, Ammori JB, Kumar AM, Biswas T, Dorth JA. Adjuvant and neoadjuvant options in resectable gastric cancer: is there an optimal treatment approach? Curr Oncol Rep 2015;17:18. [PMID: 25708803 DOI: 10.1007/s11912-015-0442-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
11 Zhai YJ, Su YP, Wang SJ, Ning FL, Wang ZB, Yu WZ, Chen SS. A phase II trial of post-operative chemoradiotherapy for completely resected gastric cancer with D2 lymphadenectomy. Oncol Lett 2014;8:1844-8. [PMID: 25202423 DOI: 10.3892/ol.2014.2382] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
12 Gong H, Chu Y, Hu Q, Song Q. Preoperative Radiotherapy Is Associated With Significant Survival Benefits for Patients With Gastric Signet Ring Cell Carcinoma: A SEER-Based Approach. Technol Cancer Res Treat 2020;19:1533033820960746. [PMID: 32945232 DOI: 10.1177/1533033820960746] [Reference Citation Analysis]
13 Ozden S, Ozgen Z, Ozyurt H, Gemici C, Yaprak G, Tepetam H, Mayadagli A. Survival in gastric cancer in relation to postoperative adjuvant therapy and determinants. World J Gastroenterol 2015;21:1222-33. [PMID: 25632196 DOI: 10.3748/wjg.v21.i4.1222] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
14 Irino T, Matsuda S, Wada N, Kawakubo H, Kitagawa Y. Essential updates 2019/2020: Perioperative and surgical management of gastric cancer. Ann Gastroenterol Surg 2021;5:162-72. [PMID: 33860136 DOI: 10.1002/ags3.12438] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Coccolini F, Montori G, Ceresoli M, Cima S, Valli MC, Nita GE, Heyer A, Catena F, Ansaloni L. Advanced gastric cancer: What we know and what we still have to learn. World J Gastroenterol. 2016;22:1139-1159. [PMID: 26811653 DOI: 10.3748/wjg.v22.i3.1139] [Cited by in CrossRef: 27] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
16 Shrikhande SV, Sirohi B, Barreto SG, Chacko RT, Parikh PM, Pautu J, Arya S, Patil P, Chilukuri SC, Ganesh B, Kaur T, Shukla D, Rath GS. Indian Council of Medical Research consensus document for the management of gastric cancer. Indian J Med Paediatr Oncol 2014;35:239-43. [PMID: 25538398 DOI: 10.4103/0971-5851.144970] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 van den Ende T, Ter Veer E, Mali RMA, van Berge Henegouwen MI, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. Prognostic and Predictive Factors for the Curative Treatment of Esophageal and Gastric Cancer in Randomized Controlled Trials: A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E530. [PMID: 31013858 DOI: 10.3390/cancers11040530] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
18 Sehdev A, Catenacci DV. Perioperative therapy for locally advanced gastroesophageal cancer: current controversies and consensus of care. J Hematol Oncol 2013;6:66. [PMID: 24010946 DOI: 10.1186/1756-8722-6-66] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
19 Fontana E, Smyth EC, Cunningham D. Esophagogastric Adenocarcinoma: Is More Chemotherapy Better? Curr Treat Options Oncol 2016;17:21. [PMID: 27032643 DOI: 10.1007/s11864-016-0395-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
20 Wang SB, Qi WX, Chen JY, Xu C, Kirova YM, Cao WG, Cai R, Cao L, Yan M, Cai G. Competing risk nomogram predicting initial loco-regional recurrence in gastric cancer patients after D2 gastrectomy. Radiat Oncol 2019;14:128. [PMID: 31315683 DOI: 10.1186/s13014-019-1332-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
21 Chuang J, Gong J, Klempner SJ, Woo Y, Chao J. Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification. J Gastrointest Oncol 2018;9:560-72. [PMID: 29998022 DOI: 10.21037/jgo.2018.03.01] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
22 Murayama Y, Oritani K, Tsutsui S. Novel CD9-targeted therapies in gastric cancer. World J Gastroenterol. 2015;21:3206-3213. [PMID: 25805926 DOI: 10.3748/wjg.v21.i11.3206] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 17] [Article Influence: 3.3] [Reference Citation Analysis]
23 Kilic L, Ordu C, Ekenel M, Yildiz I, Keskin S, Sen F, Gural Z, Asoglu O, Kizir A, Aykan F. Comparison of two different adjuvant treatment modalities for pN3 gastric cancer patients after D2 lymph node dissection: can we avoid radiotherapy in a subgroup of patients? Med Oncol. 2013;30:660. [PMID: 23877872 DOI: 10.1007/s12032-013-0660-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
24 Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel) 2021;13:582. [PMID: 33540736 DOI: 10.3390/cancers13030582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Yang W, Hu R, Li GC, Zhou ML, Wang Y, Shen LJ, Liang LP, Zhang Z. Survival outcomes and patterns of failure after D2 dissection and adjuvant chemoradiotherapy for locally advanced gastric cancer: a retrospective study. Br J Radiol 2018;91:20170594. [PMID: 29927628 DOI: 10.1259/bjr.20170594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
26 Uyeturk U, Arslan SH, Bal O, Arslan UY, Oksuzoglu OB. Isolated ovarian metastasis of gastric cancer: Krukenberg tumor. Contemp Oncol (Pozn) 2013;17:515-9. [PMID: 24592139 DOI: 10.5114/wo.2013.37542] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Qian J, Qian Y, Wang J, Gu B, Pei D, He S, Zhu F, Røe OD, Xu J, Liu L, Gu Y, Guo R, Yin Y, Shu Y, Chen X. A clinical prognostic scoring system for resectable gastric cancer to predict survival and benefit from paclitaxel- or oxaliplatin-based adjuvant chemotherapy. Drug Des Devel Ther 2016;10:241-58. [PMID: 26966350 DOI: 10.2147/DDDT.S88743] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
28 Cao Y, Zhang G, Wang P, Zhou J, Gan W, Song Y, Huang L, Zhang Y, Luo G, Gong J, Zhang L. Clinical significance of UGT1A1 polymorphism and expression of ERCC1, BRCA1, TYMS, RRM1, TUBB3, STMN1 and TOP2A in gastric cancer. BMC Gastroenterol 2017;17:2. [PMID: 28056823 DOI: 10.1186/s12876-016-0561-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
29 Ao S, Wang Y, Song Q, Ye Y, Lyu G. Current status and future perspectives on neoadjuvant therapy in gastric cancer. Chin J Cancer Res 2021;33:181-92. [PMID: 34158738 DOI: 10.21147/j.issn.1000-9604.2021.02.06] [Reference Citation Analysis]
30 Iyer P, Moslim M, Farma JM, Denlinger CS. Diffuse gastric cancer: histologic, molecular, and genetic basis of disease. Transl Gastroenterol Hepatol 2020;5:52. [PMID: 33073047 DOI: 10.21037/tgh.2020.01.02] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
31 Sai S, Wakai T, Vares G, Yamada S, Kamijo T, Kamada T, Shirai T. Combination of carbon ion beam and gemcitabine causes irreparable DNA damage and death of radioresistant pancreatic cancer stem-like cells in vitro and in vivo. Oncotarget. 2015;6:5517-5535. [PMID: 25849939 DOI: 10.18632/oncotarget.3584] [Cited by in Crossref: 33] [Cited by in F6Publishing: 27] [Article Influence: 6.6] [Reference Citation Analysis]
32 Wang X, Tian Y, Tang Y, Hu ZH, Zhang JJ, Fu GS, Ma P, Ren H, Zhang T, Li N, Liu WY, Fang H, Li YX, Jin J. Tomotherapy as an adjuvant treatment for gastroesophageal junction and stomach cancer may reduce bowel and bone marrow toxicity compared to intensity-modulated radiotherapy and volumetric-modulated arc therapy.Oncotarget. 2017;8:39727-39735. [PMID: 28061474 DOI: 10.18632/oncotarget.14459] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
33 Song X, Shi Y, Shi T, Liu B, Wei J, Wang J. The efficacy of treating patients with non-metastatic gastric linitis plastica using surgery with chemotherapy and/or radiotherapy. Ann Transl Med 2020;8:1433. [PMID: 33313178 DOI: 10.21037/atm-20-2785b] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Wang X, Shen Y, Zhu H, Zhao Y, Li Z, Qiu M, Li Q, Gou H, Yang Y, Cao D, Liu J, Yi C, Liao Z, Luo D, Bi F, Xu F. A phase II trial of concurrent 3D-CRT/IMRT and oxaliplatin, 5-fluorouracil and leucovorin (FOLFOX) in gastric cancer patients with R0 gastrectomy and D2 lymph node dissection. Gastric Cancer 2016;19:245-54. [PMID: 25609451 DOI: 10.1007/s10120-015-0461-8] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
35 Li G, Zhang Z, Ma X, Zhu J, Cai G. Postoperative chemoradiotherapy combined with epirubicin-based triplet chemotherapy for locally advanced adenocarcinoma of the stomach or gastroesophageal junction. PLoS One 2013;8:e54233. [PMID: 23372688 DOI: 10.1371/journal.pone.0054233] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
36 Kersting S, Konopke R, Dittert D, Distler M, Rückert F, Gastmeier J, Baretton GB, Saeger HD. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma? J Gastroenterol Hepatol 2009;24:886-95. [PMID: 19655439 DOI: 10.1111/j.1440-1746.2008.05732.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
37 Peng J, Wei Y, Zhou F, Dai J, Zhong Y, Xie C, Qin Y, Gong J, Xiong B, Zhou Y. D2-resected stage IIIc gastric cancer patients benefit from adjuvant chemoradiotherapy. Cancer Med. 2016;5:2773-2780. [PMID: 27666138 DOI: 10.1002/cam4.873] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
38 Liu Y, Ling Y, Qi Q, Zhu M, Wan M, Zhang Y, Zhang C. Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins. Oncol Lett 2015;9:999-1005. [PMID: 25624920 DOI: 10.3892/ol.2014.2793] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
39 Tu CC, Hsu PK. The frontline of esophageal cancer treatment: questions to be asked and answered. Ann Transl Med 2018;6:83. [PMID: 29666806 DOI: 10.21037/atm.2017.10.31] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
40 Zhi Y, Lin Z, Ma J, Mou W, Chen X. Distinguish the Role of Radiotherapy From Chemoradiotherapy for Gastric Cancer With Behavior of Metastasis-Indolent in Lymph Node. Technol Cancer Res Treat 2020;19:1533033820959400. [PMID: 33148125 DOI: 10.1177/1533033820959400] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Zurlo IV, Basso M, Strippoli A, Calegari MA, Orlandi A, Cassano A, Di Salvatore M, Garufi G, Bria E, Tortora G, Barone C, Pozzo C. Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era? Cancers (Basel) 2020;12:E1749. [PMID: 32630186 DOI: 10.3390/cancers12071749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
42 Samalin E, Ychou M. Neoadjuvant therapy for gastroesophageal adenocarcinoma. World J Clin Oncol 2016;7:284-92. [PMID: 27298768 DOI: 10.5306/wjco.v7.i3.284] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
43 Kanaji S, Suzuki S, Matsuda Y, Hasegawa H, Yamamoto M, Yamashita K, Oshikiri T, Matsuda T, Nakamura T, Sumi Y, Kakeji Y. Recent updates in perioperative chemotherapy and recurrence pattern of gastric cancer. Ann Gastroenterol Surg. 2018;2:400-405. [PMID: 30460342 DOI: 10.1002/ags3.12199] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
44 Yang Y, Ma Y, Xiang X, Xing P, Wu Y, Zhang L, Tian Y. The prognostic value of the lymph node ratio for local advanced gastric cancer patients with intensity-modulated radiation therapy and concurrent chemotherapy after radical gastrectomy in China. Radiat Oncol 2020;15:237. [PMID: 33054848 DOI: 10.1186/s13014-020-01687-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
45 Krasniqi E, Pellicori S, Formica V. Emerging role of S-1 in gastric cancer. Indian J Med Paediatr Oncol 2015;36:219-28. [PMID: 26811591 DOI: 10.4103/0971-5851.171542] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhu R, Liu F, Grisotti G, Perez-Irizarry J, Salem RR, Cha CH, Johung KL, Boffa DJ, Zhang Y, Khan SA. Clinical impact of underutilization of adjuvant therapy in node positive gastric adenocarcinoma. J Gastrointest Oncol 2018;9:517-26. [PMID: 29998017 DOI: 10.21037/jgo.2018.03.05] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
47 Zhang N, Fei Q, Gu J, Yin L, He X. Progress of preoperative and postoperative radiotherapy in gastric cancer. World J Surg Oncol 2018;16:187. [PMID: 30213266 DOI: 10.1186/s12957-018-1490-7] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
48 Fan M, Hu W, Zhang Z. Chemoradiation for gastric cancer: controversies, updates and novel techniques. Br J Radiol 2015;88:20150027. [PMID: 25827208 DOI: 10.1259/bjr.20150027] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
49 Elimova E, Shiozaki H, Wadhwa R, Sudo K, Chen Q, Estrella JS, Blum MA, Badgwell B, Das P, Song S, Ajani JA. Medical management of gastric cancer: a 2014 update. World J Gastroenterol 2014;20:13637-47. [PMID: 25320502 DOI: 10.3748/wjg.v20.i38.13637] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 22] [Article Influence: 4.3] [Reference Citation Analysis]
50 Liu G, Zhao H, Ding Q, Li H, Liu T, Yang H, Liu Y. CDK6 is stimulated by hyperthermia and protects gastric cancer cells from hyperthermia‑induced damage. Mol Med Rep 2021;23:240. [PMID: 33537819 DOI: 10.3892/mmr.2021.11879] [Reference Citation Analysis]
51 Huang T, Luo X, Wu B, Peng P, Dai Y, Hu G, Qiu H, Yuan X. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells. Oncol Rep 2020;44:2634-44. [PMID: 33125154 DOI: 10.3892/or.2020.7820] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
52 Zhou J, Wu X, Li G, Gao X, Zhai M, Chen W, Hu H, Tang Z. Prediction of radiosensitive patients with gastric cancer by developing gene signature. Int J Oncol 2017;51:1067-76. [PMID: 28902346 DOI: 10.3892/ijo.2017.4107] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
53 Martínez-Lago N, Vieito-Villar M, Vidal-Insua Y, Padin-Iruegas ME, Vazquez-Rivera F, Candamio-Folgar S, Lopez-Lopez R. Adjuvant treatment with infusional 5-fluorouracil in high risk adenocarcinoma of the stomach or gastroesophageal junction. Clin Transl Oncol 2015;17:856-61. [PMID: 26133519 DOI: 10.1007/s12094-015-1314-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
54 Gao K, Wu J. National trend of gastric cancer mortality in China (2003-2015): a population-based study.Cancer Commun (Lond). 2019;39:24. [PMID: 31046840 DOI: 10.1186/s40880-019-0372-x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 10] [Article Influence: 13.0] [Reference Citation Analysis]
55 Xiang XS, Su Y, Li GL, Ma L, Zhou CS, Ma RF. Phase II Study of Preoperative Intra-Arterial Epirubicin, Etoposide, and Oxaliplatin Combined with Oral S-1 Chemotherapy for the Treatment of Borrmann Type 4 Gastric Cancer. J Gastric Cancer 2020;20:395-407. [PMID: 33425441 DOI: 10.5230/jgc.2020.20.e40] [Reference Citation Analysis]
56 Calvo FA, Sole CV, Obregón R, Gómez-Espí M, González-San Segundo C, González-Bayón L, Alvarez E, García-Sabrido JL. Intraoperative radiotherapy for the treatment of resectable locally advanced gastric adenocarcinoma: topography of locoregional recurrences and long-term outcomes. Clin Transl Oncol 2013;15:443-9. [PMID: 23143948 DOI: 10.1007/s12094-012-0949-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
57 Fornaro L, Spallanzani A, de Vita F, D'Ugo D, Falcone A, Lorenzon L, Tirino G, Cascinu S; GAIN (GAstric Cancer Italian Network). Beyond the Guidelines: The Grey Zones of the Management of Gastric Cancer. Consensus Statements from the Gastric Cancer Italian Network (GAIN). Cancers (Basel) 2021;13:1304. [PMID: 33804024 DOI: 10.3390/cancers13061304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Yeh JM, Tramontano AC, Hur C, Schrag D. Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER-Medicare study. Gastric Cancer 2017;20:811-24. [PMID: 28205057 DOI: 10.1007/s10120-017-0693-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
59 Charalampakis N, Economopoulou P, Kotsantis I, Tolia M, Schizas D, Liakakos T, Elimova E, Ajani JA, Psyrri A. Medical management of gastric cancer: a 2017 update. Cancer Med. 2018;7:123-133. [PMID: 29239137 DOI: 10.1002/cam4.1274] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 18.0] [Reference Citation Analysis]
60 Lago NM, Villar MV, Ponte RV, Nallib IA, Alvarez JJC, López JRA, López RL, Iruegas MEP. Impact of HER2 status in resected gastric or gastroesophageal junction adenocarcinoma in a Western population. Ecancermedicalscience 2020;14:1020. [PMID: 32256703 DOI: 10.3332/ecancer.2020.1020] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Fan M, Li G, Shen L, Zhang H, Liang L, Zhang Z. Identification of patients with lymph node metastasis from gastric cancer who may benefit from adjuvant chemoradiotherapy after D2 dissection--do N3 patients benefit from additional radiation? Br J Radiol 2016;89:20150758. [PMID: 26728420 DOI: 10.1259/bjr.20150758] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
62 Badiyan SN, Hallemeier CL, Lin SH, Hall MD, Chuong MD. Proton beam therapy for gastrointestinal cancers: past, present, and future. J Gastrointest Oncol 2018;9:962-71. [PMID: 30505599 DOI: 10.21037/jgo.2017.11.07] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
63 Slagter AE, Vollebergh MA, Jansen EPM, van Sandick JW, Cats A, van Grieken NCT, Verheij M. Towards Personalization in the Curative Treatment of Gastric Cancer. Front Oncol. 2020;10:614907. [PMID: 33330111 DOI: 10.3389/fonc.2020.614907] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
64 Jácome AA, Coutinho AK, Lima EM, Andrade AC, Dos Santos JS. Personalized medicine in gastric cancer: Where are we and where are we going? World J Gastroenterol. 2016;22:1160-1171. [PMID: 26811654 DOI: 10.3748/wjg.v22.i3.1160] [Cited by in CrossRef: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
65 Martin-Richard M, Custodio A, García-Girón C, Grávalos C, Gomez C, Jimenez-Fonseca P, Manzano JL, Pericay C, Rivera F, Carrato A. Seom guidelines for the treatment of gastric cancer 2015. Clin Transl Oncol 2015;17:996-1004. [PMID: 26691658 DOI: 10.1007/s12094-015-1456-y] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
66 Stark AP, Blum MM, Chiang YJ, Das P, Minsky BD, Estrella JS, Ajani JA, Badgwell BD, Mansfield P, Ikoma N. Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer. J Gastric Cancer 2020;20:313-27. [PMID: 33024587 DOI: 10.5230/jgc.2020.20.e29] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
67 Kim DW, Kwon OK, Yoo MW, Ryu SW, Oh SJ, Hur H, Hwang SH, Lee J, Jin SH, Lee SE, Kim JH, Kim JJ, Jeong IH, Jee YS. Actual compliance to adjuvant chemotherapy in gastric cancer. Ann Surg Treat Res 2019;96:185-90. [PMID: 30941322 DOI: 10.4174/astr.2019.96.4.185] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
68 Sawayama H, Iwatsuki M, Kuroda D, Toihata T, Uchihara T, Koga Y, Yagi T, Kiyozumi Y, Eto T, Hiyoshi Y, Ishimoto T, Baba Y, Miyamoto Y, Yoshida N, Baba H. The association of the lymph node ratio and serum carbohydrate antigen 19-9 with early recurrence after curative gastrectomy for gastric cancer. Surg Today 2018;48:994-1003. [PMID: 29926189 DOI: 10.1007/s00595-018-1684-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
69 Khorfan R, Schlick CJR, Yang AD, Odell DD, Bentrem DJ, Merkow RP. Utilization of Minimally Invasive Surgery and Its Association with Chemotherapy for Locally Advanced Gastric Cancer. J Gastrointest Surg 2020;24:243-52. [PMID: 31749097 DOI: 10.1007/s11605-019-04410-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
70 Bauer K, Schroeder M, Porzsolt F, Henne-Bruns D. Comparison of international guidelines on the accompanying therapy for advanced gastric cancer: reasons for the differences. J Gastric Cancer. 2015;15:10-18. [PMID: 25861518 DOI: 10.5230/jgc.2015.15.1.10] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
71 Luo H, Cui YY, Zhang JG, Sun YN, Zheng XL, Yang CL, Ye K, Ge H. Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma. Clin Transl Oncol 2018;20:889-98. [PMID: 29143229 DOI: 10.1007/s12094-017-1803-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
72 Jácome AA, Sankarankutty AK, dos Santos JS. Adjuvant therapy for gastric cancer: what have we learned since INT0116? World J Gastroenterol 2015;21:3850-9. [PMID: 25852269 DOI: 10.3748/wjg.v21.i13.3850] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
73 Choi AH, Kim J, Chao J. Perioperative chemotherapy for resectable gastric cancer: MAGIC and beyond. World J Gastroenterol. 2015;21:7343-7348. [PMID: 26139980 DOI: 10.3748/wjg.v21.i24.7343] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 34] [Article Influence: 8.6] [Reference Citation Analysis]
74 Charalampakis N, Nogueras González GM, Elimova E, Wadhwa R, Shiozaki H, Shimodaira Y, Blum MA, Rogers JE, Harada K, Matamoros A Jr, Sagebiel T, Das P, Minsky BD, Lee JH, Weston B, Bhutani MS, Estrella JS, Badgwell BD, Ajani JA. The Proportion of Signet Ring Cell Component in Patients with Localized Gastric Adenocarcinoma Correlates with the Degree of Response to Pre-Operative Chemoradiation. Oncology 2016;90:239-47. [PMID: 27046280 DOI: 10.1159/000443506] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
75 Kim JH, Park SR, Ryu MH, Ryoo BY, Kim KP, Kim BS, Yoo MW, Yook JH, Kim BS, Kim J. Phase II Study of Induction Chemotherapy with Docetaxel, Capecitabine, and Cisplatin Plus Bevacizumab for Initially Unresectable Gastric Cancer with Invasion of Adjacent Organs or Paraaortic Lymph Node Metastasis. Cancer Res Treat. 2018;50:518-529. [PMID: 28546521 DOI: 10.4143/crt.2017.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
76 Chen H, Wu S, Kundra A, Aja Onu I, Gotlieb V, Wang JC. Gastric Perforation in a Patient Receiving Neoadjuvant Chemoradiotherapy. World J Oncol 2015;6:383-6. [PMID: 28983335 DOI: 10.14740/wjon924w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
77 Yu JI, Lim DH, Lee J, Kang WK, Park SH, Park JO, Park YS, Lim HY, Kim ST, Lee SJ, Kim S, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Yoo H, Kim K. Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node-Positive Gastric Cancer Treated with Different Adjuvant Protocols. Cancer Res Treat 2019;51:876-85. [PMID: 30282450 DOI: 10.4143/crt.2018.401] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
78 Sharfo AWM, Stieler F, Kupfer O, Heijmen BJM, Dirkx MLP, Breedveld S, Wenz F, Lohr F, Boda-Heggemann J, Buergy D. Automated VMAT planning for postoperative adjuvant treatment of advanced gastric cancer. Radiat Oncol 2018;13:74. [PMID: 29685166 DOI: 10.1186/s13014-018-1032-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
79 van der Kaaij RT, Braam HJ, Boot H, Los M, Cats A, Grootscholten C, Schellens JH, Aalbers AG, Huitema AD, Knibbe CA, Boerma D, Wiezer MJ, van Ramshorst B, van Sandick JW. Treatment of Peritoneal Dissemination in Stomach Cancer Patients With Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): Rationale and Design of the PERISCOPE Study. JMIR Res Protoc 2017;6:e136. [PMID: 28705789 DOI: 10.2196/resprot.7790] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
80 Yuan SQ, Wu WJ, Qiu MZ, Wang ZX, Yang LP, Jin Y, Yun JP, Gao YH, Li YH, Zhou ZW, Wang F, Xu RH. Development and Validation of a Nomogram to Predict the Benefit of Adjuvant Radiotherapy for Patients with Resected Gastric Cancer. J Cancer 2017;8:3498-505. [PMID: 29151934 DOI: 10.7150/jca.19879] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
81 Minnella EM, Awasthi R, Loiselle SE, Agnihotram RV, Ferri LE, Carli F. Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial. JAMA Surg 2018;153:1081-9. [PMID: 30193337 DOI: 10.1001/jamasurg.2018.1645] [Cited by in Crossref: 95] [Cited by in F6Publishing: 71] [Article Influence: 47.5] [Reference Citation Analysis]
82 Batista TP, de Mendonça LM, Fassizoli-Fonte AL. The role of perioperative radiotherapy in gastric cancer. Oncol Rev 2012;6:e23. [PMID: 25992221 DOI: 10.4081/oncol.2012.e23] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
83 Ren F, Li S, Zhang Y, Zhao Z, Wang H, Cui Y, Wang M. Efficacy and safety of intensity-modulated radiation therapy versus three-dimensional conformal radiation treatment for patients with gastric cancer: a systematic review and meta-analysis. Radiat Oncol 2019;14:84. [PMID: 31118042 DOI: 10.1186/s13014-019-1294-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
84 Calvo FA, Sole CV, Marsiglia H, Alvarado E, Ferrer C, Czito B. Intraoperative radiotherapy for gastrointestinal malignancies: contemporary outcomes with multimodality therapy. Curr Oncol Rep 2015;17:419. [PMID: 25416313 DOI: 10.1007/s11912-014-0419-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
85 Quadri HS, Smaglo BG, Morales SJ, Phillips AC, Martin AD, Chalhoub WM, Haddad NG, Unger KR, Levy AD, Al-Refaie WB. Gastric Adenocarcinoma: A Multimodal Approach.Front Surg. 2017;4:42. [PMID: 28824918 DOI: 10.3389/fsurg.2017.00042] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
86 Johnston FM, Beckman M. Updates on Management of Gastric Cancer. Curr Oncol Rep 2019;21:67. [PMID: 31236716 DOI: 10.1007/s11912-019-0820-4] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 21.0] [Reference Citation Analysis]
87 Zhang T, Liang ZW, Han J, Bi JP, Yang ZY, Ma H. Double-arc volumetric modulated therapy improves dose distribution compared to static gantry IMRT and 3D conformal radiotherapy for adjuvant therapy of gastric cancer. Radiat Oncol 2015;10:114. [PMID: 25986069 DOI: 10.1186/s13014-015-0420-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
88 Song S, Chie EK, Kim K, Lee HJ, Yang HK, Han SW, Oh DY, Im SA, Bang YJ, Ha SW. Postoperative chemoradiotherapy in high risk locally advanced gastric cancer. Radiat Oncol J 2012;30:213-7. [PMID: 23346541 DOI: 10.3857/roj.2012.30.4.213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
89 Aggarwal A, Chopra S, Paul SN, Engineer R, Srivastava SK. Evaluation of internal target volume in patients undergoing image-guided intensity modulated adjuvant radiation for gastric cancers. Br J Radiol 2014;87:20130583. [PMID: 24288401 DOI: 10.1259/bjr.20130583] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
90 Lohr F, Georg D, Cozzi L, Eich HT, Weber DC, Koeck J, Knäusl B, Dieckmann K, Abo-Madyan Y, Fiandra C, Mueller RP, Engert A, Ricardi U. Novel radiotherapy techniques for involved-field and involved-node treatment of mediastinal Hodgkin lymphoma: when should they be considered and which questions remain open? Strahlenther Onkol 2014;190:864-6, 868-71. [PMID: 25209551 DOI: 10.1007/s00066-014-0719-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
91 Sugisawa N, Tokunaga M, Makuuchi R, Miki Y, Tanizawa Y, Bando E, Kawamura T, Terashima M. A phase II study of an enhanced recovery after surgery protocol in gastric cancer surgery. Gastric Cancer. 2016;19:961-967. [PMID: 26260875 DOI: 10.1007/s10120-015-0528-6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
92 Qin RQ, Wen YS, Wang WP, Xi KX, Yu XY, Zhang LJ. The role of postoperative adjuvant chemotherapy for lymph node-positive esophageal squamous cell carcinoma: a propensity score matching analysis. Med Oncol. 2016;33:31. [PMID: 26922662 DOI: 10.1007/s12032-016-0746-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
93 Saragoni L. Upgrading the definition of early gastric cancer: better staging means more appropriate treatment. Cancer Biol Med 2015;12:355-61. [PMID: 26779372 DOI: 10.7497/j.issn.2095-3941.2015.0054] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
94 Hao Y, Yu P, Qian F, Zhao Y, Shi Y, Tang B, Zeng D, Zhang C. Comparison of laparoscopy-assisted and open radical gastrectomy for advanced gastric cancer: A retrospective study in a single minimally invasive surgery center. Medicine (Baltimore) 2016;95:e3936. [PMID: 27336885 DOI: 10.1097/MD.0000000000003936] [Cited by in Crossref: 24] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
95 Buergy D, Lohr F, Baack T, Siebenlist K, Haneder S, Michaely H, Wenz F, Boda-Heggemann J. Radiotherapy for tumors of the stomach and gastroesophageal junction--a review of its role in multimodal therapy. Radiat Oncol. 2012;7:192. [PMID: 23157945 DOI: 10.1186/1748-717x-7-192] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
96 Kim Y, Squires MH, Poultsides GA, Fields RC, Weber SM, Votanopoulos KI, Kooby DA, Worhunsky DJ, Jin LX, Hawkins WG, Acher AW, Cho CS, Saunders N, Levine EA, Schmidt CR, Maithel SK, Pawlik TM. Impact of lymph node ratio in selecting patients with resected gastric cancer for adjuvant therapy. Surgery 2017;162:285-94. [PMID: 28578142 DOI: 10.1016/j.surg.2017.03.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
97 Toneto MG, Viola L. CURRENT STATUS OF THE MULTIDISCIPLINARY TREATMENT OF GASTRIC ADENOCARCINOMA. Arq Bras Cir Dig 2018;31:e1373. [PMID: 29972401 DOI: 10.1590/0102-672020180001e1373] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
98 Ostwal V, Sahu A, Ramaswamy A, Sirohi B, Bose S, Talreja V, Goel M, Patkar S, Desouza A, Shrikhande SV. Perioperative Epirubicin, Oxaliplatin, and Capecitabine Chemotherapy in Locally Advanced Gastric Cancer: Safety and Feasibility in an Interim Survival Analysis. J Gastric Cancer 2017;17:21-32. [PMID: 28337360 DOI: 10.5230/jgc.2017.17.e3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
99 Hensel F, Timmermann W, von Rahden BH, Rosenwald A, Brändlein S, Illert B. Ten-year follow-up of a prospective trial for the targeted therapy of gastric cancer with the human monoclonal antibody PAT-SC1. Oncol Rep 2014;31:1059-66. [PMID: 24452482 DOI: 10.3892/or.2014.2987] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
100 Fuse N, Bando H, Chin K, Ito S, Yoshikawa T, Tsuburaya A, Terashima M, Kawashima Y, Fukunaga T, Gotoh M, Emi Y, Yoshida K, Oki E, Takahashi S, Kuriki H, Sato K, Sasako M. Adjuvant capecitabine plus oxaliplatin after D2 gastrectomy in Japanese patients with gastric cancer: a phase II study. Gastric Cancer. 2017;20:332-340. [PMID: 26956689 DOI: 10.1007/s10120-016-0606-4] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]
101 Duan S, Wang P, Liu F, Huang H, An W, Pan S, Wang X. Novel immune-risk score of gastric cancer: A molecular prediction model combining the value of immune-risk status and chemosensitivity. Cancer Med 2019;8:2675-85. [PMID: 30945466 DOI: 10.1002/cam4.2077] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
102 Quan R, Huang J, Chen H, Liao Y, Lv W, Chen N, Liu J, Zhang H, Xu D. Comparison of efficacy in adjuvant chemotherapy regimens in patients with radically resected gastric cancer : a propensity-matched analysis. Oncotarget 2016;7:76316-26. [PMID: 27602756 DOI: 10.18632/oncotarget.11783] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
103 Nakajima T, Fujii M. What make differences in the outcome of adjuvant treatments for resected gastric cancer? World J Gastroenterol 2014;20:11567-73. [PMID: 25206264 DOI: 10.3748/wjg.v20.i33.11567] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
104 Girardi DM, de Lima MA, Pereira GCB, Negrão MV, López RVM, Capareli FC, Sabbaga J, Hoff PMG. Chemoradiotherapy versus chemotherapy as adjuvant treatment for localized gastric cancer: a propensity score-matched analysis. BMC Cancer 2018;18:378. [PMID: 29614980 DOI: 10.1186/s12885-018-4305-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
105 Nakamura K, Kuwata T, Shimoda T, Mizusawa J, Katayama H, Kushima R, Taniguchi H, Sano T, Sasako M, Fukuda H. Determination of the optimal cutoff percentage of residual tumors to define the pathological response rate for gastric cancer treated with preoperative therapy (JCOG1004-A). Gastric Cancer. 2015;18:597-604. [PMID: 24968818 DOI: 10.1007/s10120-014-0401-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
106 Elimova E, Slack RS, Chen HC, Planjery V, Shiozaki H, Shimodaira Y, Charalampakis N, Lin Q, Harada K, Wadhwa R, Estrella JS, Kaya DM, Sagebiel T, Lee JH, Weston B, Bhutani M, Murphy MB, Matamoros A, Minsky B, Das P, Mansfield PF, Badgwell BD, Ajani JA. Patterns of relapse in patients with localized gastric adenocarcinoma who had surgery with or without adjunctive therapy: costs and effectiveness of surveillance. Oncotarget 2017;8:81430-40. [PMID: 29113402 DOI: 10.18632/oncotarget.19226] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
107 Wang SB, Qi WX, Chen JY, Xu C, Cao WG, Cai R, Cao L, Cai G. Identification of Patients With Locally Advanced Gastric Cancer Who May Benefit From Adjuvant Chemoradiotherapy After D2 dissection: A Propensity Score Matching Analysis. Front Oncol 2021;11:648978. [PMID: 33869049 DOI: 10.3389/fonc.2021.648978] [Reference Citation Analysis]
108 González-Domingo M, Ulloa C, Olivares J, Estrada S, González P, Cardozo N. Adjuvant radiochemotherapy in locally advanced gastric cancer: from evidence to daily clinical practice in a single institution. Ecancermedicalscience 2020;14:1137. [PMID: 33281929 DOI: 10.3332/ecancer.2020.1137] [Reference Citation Analysis]
109 Kwon MJ, Kim RN, Song K, Jeon S, Jeong HM, Kim JS, Han J, Hong S, Oh E, Choi JS, An J, Pollack JR, Choi YL, Park CK, Shin YK. Genes co-amplified with ERBB2 or MET as novel potential cancer-promoting genes in gastric cancer. Oncotarget 2017;8:92209-26. [PMID: 29190909 DOI: 10.18632/oncotarget.21150] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.8] [Reference Citation Analysis]
110 Boda-Heggemann J, Weiss C, Schneider V, Hofheinz RD, Haneder S, Michaely H, Wertz H, Ronellenfitsch U, Hochhaus A, Wenz F, Lohr F. Adjuvant IMRT/XELOX radiochemotherapy improves long-term overall- and disease-free survival in advanced gastric cancer. Strahlenther Onkol 2013;189:417-23. [PMID: 23558673 DOI: 10.1007/s00066-013-0309-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.0] [Reference Citation Analysis]
111 Wang QW, Zhang XT, Lu M, Shen L. Impact of duration of adjuvant chemotherapy in radically resected patients with T4bN1-3M0/TxN3bM0 gastric cancer. World J Gastrointest Oncol 2018;10:31-9. [PMID: 29375746 DOI: 10.4251/wjgo.v10.i1.31] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
112 Wei F, Lyu H, Wang S, Chu Y, Chen F. Postoperative Radiotherapy Improves Survival in Gastric Signet-Ring Cell Carcinoma: a SEER Database Analysis. J Gastric Cancer 2019;19:393-407. [PMID: 31897342 DOI: 10.5230/jgc.2019.19.e36] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
113 Goetze OT, Al-Batran SE, Chevallay M, Mönig SP. Multimodal treatment in locally advanced gastric cancer. Updates Surg 2018;70:173-9. [PMID: 29946806 DOI: 10.1007/s13304-018-0539-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
114 Smyth EC, Cunningham D. Operable gastro-oesophageal junctional adenocarcinoma: Where to next? World J Gastrointest Oncol 2014;6:145-55. [PMID: 24936225 DOI: 10.4251/wjgo.v6.i6.145] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
115 Mrena J, Mattila A, Böhm J, Jantunen I, Kellokumpu I. Surgical care quality and oncologic outcome after D2 gastrectomy for gastric cancer. World J Gastroenterol 2015;21:13294-301. [PMID: 26715812 DOI: 10.3748/wjg.v21.i47.13294] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
116 Ning ZK, Hu CG, Huang C, Liu J, Zhou TC, Zong Z. Molecular Subtypes and CD4+ Memory T Cell-Based Signature Associated With Clinical Outcomes in Gastric Cancer. Front Oncol 2020;10:626912. [PMID: 33816214 DOI: 10.3389/fonc.2020.626912] [Reference Citation Analysis]
117 Cai Z, Yin Y, Yin Y, Shen C, Wang J, Yin X, Chen Z, Zhou Y, Zhang B. Comparative effectiveness of adjuvant treatments for resected gastric cancer: a network meta-analysis. Gastric Cancer 2018;21:1031-40. [PMID: 29728791 DOI: 10.1007/s10120-018-0831-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
118 Pan S, Yin S, Zhu Z, Liu F, Xu H. Decision-making of adjuvant therapy in pT1N1M0 gastric cancer: Should radiotherapy be added to chemotherapy? A propensity score-matched analysis. J Cancer 2021;12:1179-89. [PMID: 33442416 DOI: 10.7150/jca.52123] [Reference Citation Analysis]
119 Liu D, Lu M, Li J, Yang Z, Feng Q, Zhou M, Zhang Z, Shen L. The patterns and timing of recurrence after curative resection for gastric cancer in China. World J Surg Oncol. 2016;14:305. [PMID: 27931221 DOI: 10.1186/s12957-016-1042-y] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
120 Moorcraft SY, Smyth EC, Cunningham D. Adjuvant or neoadjuvant therapy for operable esophagogastric cancer? Gastric Cancer 2015;18:1-10. [PMID: 24638977 DOI: 10.1007/s10120-014-0356-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
121 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Chang JS, Koom WS, Lee Y, Yoon HI, Lee HS. Postoperative adjuvant chemoradiotherapy in D2-dissected gastric cancer: is radiotherapy necessary after D2-dissection? World J Gastroenterol. 2014;20:12900-12907. [PMID: 25278687 DOI: 10.3748/wjg.v20.i36.12900] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
123 Yi JH, Kang JH, Hwang IG, Ahn HK, Baek HJ, Lee SI, Lim DH, Won YW, Ji JH, Kim HS, Rha SY, Oh SY, Lee KE, Lim T, Maeng CH, Kim MJ, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK, Park SH. A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. Cancer Res Treat 2016;48:553-60. [PMID: 26323641 DOI: 10.4143/crt.2015.155] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
124 Borg D, Hedner C, Gaber A, Nodin B, Fristedt R, Jirström K, Eberhard J, Johnsson A. Expression of IFITM1 as a prognostic biomarker in resected gastric and esophageal adenocarcinoma. Biomark Res 2016;4:10. [PMID: 27186374 DOI: 10.1186/s40364-016-0064-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.6] [Reference Citation Analysis]
125 Ford H, Gounaris I. Docetaxel and its potential in the treatment of refractory esophagogastric adenocarcinoma. Therap Adv Gastroenterol 2015;8:189-205. [PMID: 26136837 DOI: 10.1177/1756283X15585468] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
126 Seshadri RA, Glehen O. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in gastric cancer. World J Gastroenterol 2016;22:1114-30. [PMID: 26811651 DOI: 10.3748/wjg.v22.i3.1114] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 24] [Article Influence: 8.5] [Reference Citation Analysis]
127 Zhou ML, Kang M, Li GC, Guo XM, Zhang Z. Postoperative chemoradiotherapy versus chemotherapy for R0 resected gastric cancer with D2 lymph node dissection: an up-to-date meta-analysis. World J Surg Oncol 2016;14:209. [PMID: 27502921 DOI: 10.1186/s12957-016-0957-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
128 Svensson MC, Warfvinge CF, Fristedt R, Hedner C, Borg D, Eberhard J, Micke P, Nodin B, Leandersson K, Jirström K. The integrative clinical impact of tumor-infiltrating T lymphocytes and NK cells in relation to B lymphocyte and plasma cell density in esophageal and gastric adenocarcinoma. Oncotarget 2017;8:72108-26. [PMID: 29069772 DOI: 10.18632/oncotarget.19437] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
129 Zhu YT, Chen XZ, Chen Y, Zhou YW, Tang LS, Luo DY, Li Q, Qiu M, Wang X, Cao D, Yang Y, Shen YL, Li ZP, Bi F, Liu JY, Gou HF. Chemoradiotherapy Is Inferior to Chemotherapy Alone in Adjuvant Setting for Signet Ring Cell Containing Gastric Cancer. Front Oncol 2020;10:570268. [PMID: 33324548 DOI: 10.3389/fonc.2020.570268] [Reference Citation Analysis]
130 Guo C, Su J, Li Z, Xiao R, Wen J, Li Y, Zhang M, Zhang X, Yu D, Huang W, Chen WD, Wang YD. The G-protein-coupled bile acid receptor Gpbar1 (TGR5) suppresses gastric cancer cell proliferation and migration through antagonizing STAT3 signaling pathway. Oncotarget 2015;6:34402-13. [PMID: 26417930 DOI: 10.18632/oncotarget.5353] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 5.4] [Reference Citation Analysis]
131 Schilsky RL. Publicly funded clinical trials and the future of cancer care. Oncologist 2013;18:232-8. [PMID: 23363807 DOI: 10.1634/theoncologist.2012-0423] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
132 Giuliani A, Miccini M, Basso L. Extent of lymphadenectomy and perioperative therapies: two open issues in gastric cancer. World J Gastroenterol 2014;20:3889-904. [PMID: 24744579 DOI: 10.3748/wjg.v20.i14.3889] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
133 Beeharry MK, Ni ZT, Yang ZY, Zheng YN, Feng RH, Liu WT, Yan C, Yao XX, Li C, Yan M, Zhu ZG. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial. BMC Cancer 2020;20:224. [PMID: 32183736 DOI: 10.1186/s12885-020-6701-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
134 Stark AP, Estrella JS, Chiang YJ, Das P, Minsky BD, Blum Murphy MA, Ajani JA, Mansfield P, Badgwell BD, Ikoma N. Impact of tumor regression grade on recurrence after preoperative chemoradiation and gastrectomy for gastric cancer. J Surg Oncol 2020;122:422-32. [PMID: 32462681 DOI: 10.1002/jso.25984] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Miao RL, Wu AW. Towards personalized perioperative treatment for advanced gastric cancer. World J Gastroenterol. 2014;20:11586-11594. [PMID: 25206266 DOI: 10.3748/wjg.v20.i33.11586] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
136 Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10:643-655. [PMID: 24061039 DOI: 10.1038/nrclinonc.2013.170] [Cited by in Crossref: 249] [Cited by in F6Publishing: 222] [Article Influence: 31.1] [Reference Citation Analysis]
137 Agolli L, Maurizi Enrici R, Osti MF. Adjuvant radiochemotherapy for gastric cancer: Should we use prognostic factors to select patients? World J Gastroenterol 2016;22:1131-8. [PMID: 26811652 DOI: 10.3748/wjg.v22.i3.1131] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
138 Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist 2013;18:1013-21. [PMID: 23966224 DOI: 10.1634/theoncologist.2012-0462] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
139 Lee JH, Chang KK, Yoon C, Tang LH, Strong VE, Yoon SS. Lauren Histologic Type Is the Most Important Factor Associated With Pattern of Recurrence Following Resection of Gastric Adenocarcinoma. Ann Surg. 2018;267:105-113. [PMID: 27759618 DOI: 10.1097/sla.0000000000002040] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 11.5] [Reference Citation Analysis]
140 Mansouri H, Zemni I, Achouri L, Mahjoub N, Ayedi MA, Ben Safta I, Ben Dhiab T, Chargui R, Rahal K. Chemoradiotherapy or chemotherapy as adjuvant treatment for resected gastric cancer: should we use selection criteria? Rep Pract Oncol Radiother 2021;26:266-80. [PMID: 34211778 DOI: 10.5603/RPOR.a2021.0040] [Reference Citation Analysis]
141 Montenegro RC, Clark PG, Howarth A, Wan X, Ceroni A, Siejka P, Nunez-Alonso GA, Monteiro O, Rogers C, Gamble V, Burbano R, Brennan PE, Tallant C, Ebner D, Fedorov O, O'Neill E, Knapp S, Dixon D, Müller S. BET inhibition as a new strategy for the treatment of gastric cancer. Oncotarget 2016;7:43997-4012. [PMID: 27259267 DOI: 10.18632/oncotarget.9766] [Cited by in Crossref: 30] [Cited by in F6Publishing: 24] [Article Influence: 10.0] [Reference Citation Analysis]
142 Santoro R, Ettorre GM, Santoro E. Subtotal gastrectomy for gastric cancer. World J Gastroenterol. 2014;20:13667-13680. [PMID: 25320505 DOI: 10.3748/wjg.v20.i38.13667] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
143 Fuchs CS, Niedzwiecki D, Mamon HJ, Tepper JE, Ye X, Swanson RS, Enzinger PC, Haller DG, Dragovich T, Alberts SR, Bjarnason GA, Willett CG, Gunderson LL, Goldberg RM, Venook AP, Ilson D, O'Reilly E, Ciombor K, Berg DJ, Meyerhardt J, Mayer RJ. Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). J Clin Oncol. 2017;35:3671-3677. [PMID: 28976791 DOI: 10.1200/jco.2017.74.2130] [Cited by in Crossref: 62] [Cited by in F6Publishing: 14] [Article Influence: 15.5] [Reference Citation Analysis]
144 Scott JG, Berglund A, Schell MJ, Mihaylov I, Fulp WJ, Yue B, Welsh E, Caudell JJ, Ahmed K, Strom TS, Mellon E, Venkat P, Johnstone P, Foekens J, Lee J, Moros E, Dalton WS, Eschrich SA, McLeod H, Harrison LB, Torres-Roca JF. A genome-based model for adjusting radiotherapy dose (GARD): a retrospective, cohort-based study. Lancet Oncol 2017;18:202-11. [PMID: 27993569 DOI: 10.1016/S1470-2045(16)30648-9] [Cited by in Crossref: 195] [Cited by in F6Publishing: 82] [Article Influence: 39.0] [Reference Citation Analysis]
145 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/an-nonc/mdt106] [Reference Citation Analysis]
146 Harada K, Baba H, Ajani JA. Recent trend in gastric cancer treatment in the USA. J Cancer Metastasis Treat 2018;4:18. [PMID: 34113719 DOI: 10.20517/2394-4722.2017.74] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
147 Liang L, Fang JY, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35:1475-1482. [PMID: 26073079 DOI: 10.1038/onc.2015.209] [Cited by in Crossref: 60] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
148 Bittoni A, Scartozzi M, Giampieri R, Faloppi L, Bianconi M, Mandolesi A, Del Prete M, Pistelli M, Cecchini L, Bearzi I, Cascinu S. Clinical evidence for three distinct gastric cancer subtypes: time for a new approach. PLoS One 2013;8:e78544. [PMID: 24265697 DOI: 10.1371/journal.pone.0078544] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
149 Mazzei MA, Bagnacci G, Gentili F, Nigri A, Pelini V, Vindigni C, Mazzei FG, Baiocchi GL, Pittiani F, Morgagni P, Petrella E, Mura G, Verdelli B, Bencivenga M, Giacopuzzi S, Marrelli D, Roviello F, Volterrani L. Gastric Cancer Maximum Tumour Diameter Reduction Rate at CT Examination as a Radiological Index for Predicting Histopathological Regression after Neoadjuvant Treatment: A Multicentre GIRCG Study. Gastroenterol Res Pract 2018;2018:1794524. [PMID: 29736166 DOI: 10.1155/2018/1794524] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.7] [Reference Citation Analysis]
150 Alsina M, Miquel JM, Diez M, Castro S, Tabernero J. How I treat gastric adenocarcinoma. ESMO Open. 2019;4:e000521. [PMID: 31354966 DOI: 10.1136/esmoopen-2019-000521] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
151 Quéro L, Guillerm S, Hennequin C. Neoadjuvant or adjuvant therapy for gastric cancer. World J Gastrointest Oncol 2015;7:102-10. [PMID: 26306142 DOI: 10.4251/wjgo.v7.i8.102] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.2] [Reference Citation Analysis]
152 Lim DH. Postoperative adjuvant radiotherapy for patients with gastric adenocarcinoma. J Gastric Cancer 2012;12:205-9. [PMID: 23346491 DOI: 10.5230/jgc.2012.12.4.205] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
153 Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014;19:1046-1055. [PMID: 25142842 DOI: 10.1634/theoncologist.2014-0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
154 Farkhondeh T, Pourbagher-Shahri AM, Azimi-Nezhad M, Forouzanfar F, Brockmueller A, Ashrafizadeh M, Talebi M, Shakibaei M, Samarghandian S. Roles of Nrf2 in Gastric Cancer: Targeting for Therapeutic Strategies. Molecules 2021;26:3157. [PMID: 34070502 DOI: 10.3390/molecules26113157] [Reference Citation Analysis]
155 Valdivieso M, Corn BW, Dancey JE, Wickerham DL, Horvath LE, Perez EA, Urton A, Cronin WM, Field E, Lackey E, Blanke CD. The Globalization of Cooperative Groups. Semin Oncol 2015;42:693-712. [PMID: 26433551 DOI: 10.1053/j.seminoncol.2015.07.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
156 Foo M, Leong T. Adjuvant therapy for gastric cancer: current and future directions. World J Gastroenterol 2014;20:13718-27. [PMID: 25320509 DOI: 10.3748/wjg.v20.i38.13718] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
157 Shum H, Rajdev L. Multimodality management of resectable gastric cancer: A review. World J Gastrointest Oncol. 2014;6:393-402. [PMID: 25320655 DOI: 10.4251/wjgo.v6.i10.393] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.7] [Reference Citation Analysis]
158 Matsuda S, Takahashi T, Fukada J, Fukuda K, Kawakubo H, Saikawa Y, Kawaguchi O, Takeuchi H, Shigematsu N, Kitagawa Y. Phase I study of neoadjuvant chemoradiotherapy with S-1 plus biweekly cisplatin for advanced gastric cancer patients with lymph node metastasis: -KOGC04-. Radiat Oncol 2014;9:9. [PMID: 24398302 DOI: 10.1186/1748-717X-9-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
159 Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, Cats A, Muller-Timmermans P, Hulshof MCCM, Boot H, Los M, Beerepoot LV, Peters FPJ, Hospers GAP, van Etten B, Hartgrink HH, van Berge Henegouwen MI, Nieuwenhuijzen GAP, van Hillegersberg R, van der Peet DL, Grabsch HI, Verheij M. CRITICS-II: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18:877. [PMID: 30200910 DOI: 10.1186/s12885-018-4770-2] [Cited by in Crossref: 47] [Cited by in F6Publishing: 38] [Article Influence: 15.7] [Reference Citation Analysis]
160 Turgeman I, Ben-Aharon I. Evolving treatment paradigms in esophageal cancer. Ann Transl Med 2021;9:903. [PMID: 34164537 DOI: 10.21037/atm.2020.03.110] [Reference Citation Analysis]
161 Mingol F, Gallego J, Orduña A, Martinez-Blasco A, Sola-Vera J, Moya P, Morcillo MA, Ruiz JA, Calpena R, Lacueva FJ. Tumor regression and survival after perioperative MAGIC-style chemotherapy in carcinoma of the stomach and gastroesophageal junction. BMC Surg 2015;15:66. [PMID: 25997454 DOI: 10.1186/s12893-015-0054-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
162 Sun Z, Shenoi MM, Nussbaum DP, Keenan JE, Gulack BC, Tyler DS, Speicher PJ, Blazer DG 3rd. Feeding jejunostomy tube placement during resection of gastric cancers. J Surg Res 2016;200:189-94. [PMID: 26248478 DOI: 10.1016/j.jss.2015.07.014] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
163 Isa N. Evidence based radiation oncology with existing technology. Rep Pract Oncol Radiother. 2014;19:259-266. [PMID: 25061519 DOI: 10.1016/j.rpor.2013.09.002] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
164 Ni C, Yang P, Guo J, Ye M. Role of DiGeorge syndrome critical region gene 9, a long noncoding RNA, in gastric cancer. Onco Targets Ther 2018;11:2259-67. [PMID: 29719408 DOI: 10.2147/OTT.S162253] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
165 Wu DM, Wang S, Wen X, Han XR, Wang YJ, Shen M, Fan SH, Zhang ZF, Zhuang J, Shan Q, Li MQ, Hu B, Sun CH, Lu J, Zheng YL. Survival Benefit of Three Different Therapies in Postoperative Patients With Advanced Gastric Cancer: A Network Meta-Analysis. Front Pharmacol 2018;9:929. [PMID: 30210338 DOI: 10.3389/fphar.2018.00929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
166 Yan H, Chen Y, Yang Z, Li Z, Che X, Xiao J, Liu Y, Qu X. An Immune Cell Signature Is Associated With Disease-Free Survival and Adjuvant Chemosensitivity of Patients With Resectable Gastric Cancer. Front Immunol 2020;11:621623. [PMID: 33613554 DOI: 10.3389/fimmu.2020.621623] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
167 Qiu M, Peng XC, Bi F, Wang X, Li Q, Xu F, Li ZP, Shen YL, Liu JY, Zhao YQ, Cao D, Gou HF, Yang Y, Chen Y, Yi C. Phase I study of postoperative radiotherapy concurrent with S-1 in patients with gastric cancer. Med Oncol 2015;32:191. [PMID: 26025485 DOI: 10.1007/s12032-015-0635-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
168 Yan Y, Xu J, Mao G. Honokiol Suppression of Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Cell Biological Activity and Its Mechanism. Med Sci Monit 2020;26:e923962. [PMID: 32862190 DOI: 10.12659/MSM.923962] [Reference Citation Analysis]
169 Li S, Zang L. The Effectiveness of Gastrectomy With Chemoradiotherapy Among Stage IV Gastric Adenocarcinoma: A Population-Based Analysis. Front Oncol 2020;10:630. [PMID: 32411605 DOI: 10.3389/fonc.2020.00630] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
170 Cartwright E, Cunningham D. The Role of Systemic Therapy in Resectable Gastric and Gastro-oesophageal Junction Cancer. Curr Treat Options Oncol 2017;18:69. [PMID: 29143893 DOI: 10.1007/s11864-017-0510-0] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
171 Barchi LC, Ramos MFKP, Dias AR, Forones NM, Carvalho MP, Castro OAP, Kassab P, Costa-Júnior WLD, Weston AC, Zilberstein B, Ferraz ÁAB, ZeideCharruf A, Brandalise A, Silva AMD, Alves B, Marins CAM, Malheiros CA, Leite CV, Bresciani CJC, Szor D, Mucerino DR, Wohnrath DR, JirjossIlias E, Martins Filho ED, PinatelLopasso F, Coimbra FJF, Felippe FEC, Tomasisch FDS, Takeda FR, Ishak G, Laporte GA, Silva HJT, Cecconello I, Rodrigues JJG, Grande JCD, Lourenço LG, Motta LMD, Ferraz LR, Moreira LF, Lopes LR, Toneto MG, Mester M, Rodrigues MAG, Franciss MY, AdamiAndreollo N, Corletta OC, Yagi OK, Malafaia O, Assumpção PP, Savassi-Rocha PR, Colleoni Neto R, Oliveira RJ, AissarSallun RA, Weschenfelder R, Oliveira SCV, Abreu TB, Castria TB, Ribeiro Junior U, Barra W, Freitas Júnior WR; Consenso. BRAZILIAN GASTRIC CANCER ASSOCIATION GUIDELINES (PART 2): UPDATE ON TREATMENT. Arq Bras Cir Dig 2021;34:e1563. [PMID: 34008707 DOI: 10.1590/0102-672020210001e1563] [Reference Citation Analysis]
172 Harada K, Lopez A, Shanbhag N, Badgwell B, Baba H, Ajani J. Recent advances in the management of gastric adenocarcinoma patients. F1000Res 2018;7:F1000 Faculty Rev-1365. [PMID: 30228868 DOI: 10.12688/f1000research.15133.1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
173 Giampieri R, Del Prete M, Cantini L, Baleani MG, Bittoni A, Maccaroni E, Berardi R. Optimal management of resected gastric cancer. Cancer Manag Res 2018;10:1605-18. [PMID: 29950898 DOI: 10.2147/CMAR.S151552] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
174 Arienti C, Pignatta S, Tesei A. Epidermal Growth Factor Receptor Family and its Role in Gastric Cancer. Front Oncol 2019;9:1308. [PMID: 31850207 DOI: 10.3389/fonc.2019.01308] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 10.5] [Reference Citation Analysis]
175 Mulder KE, Ahmed S, Davies JD, Doll CM, Dowden S, Gill S, Gordon V, Hebbard P, Lim H, McFadden A, McGhie JP, Park J, Wong R. Report from the 17th Annual Western Canadian Gastrointestinal Cancer Consensus Conference; Edmonton, Alberta; 11-12 September 2015. Curr Oncol. 2016;23:425-434. [PMID: 28050139 DOI: 10.3747/co.23.3384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
176 Altorki N, Harrison S. What is the role of neoadjuvant chemotherapy, radiation, and adjuvant treatment in resectable esophageal cancer? Ann Cardiothorac Surg. 2017;6:167-174. [PMID: 28447006 DOI: 10.21037/acs.2017.03.16] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 3.5] [Reference Citation Analysis]
177 Koerfer J, Kallendrusch S, Merz F, Wittekind C, Kubick C, Kassahun WT, Schumacher G, Moebius C, Gaßler N, Schopow N, Geister D, Wiechmann V, Weimann A, Eckmann C, Aigner A, Bechmann I, Lordick F. Organotypic slice cultures of human gastric and esophagogastric junction cancer. Cancer Med 2016;5:1444-53. [PMID: 27073068 DOI: 10.1002/cam4.720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 6.4] [Reference Citation Analysis]
178 Soyfer V, Geva R, Michelson M, Inbar M, Shacham-Shmueli E, Corn BW. The impact of overall radiotherapy treatment time and delay in initiation of radiotherapy on local control and distant metastases in gastric cancer. Radiat Oncol 2014;9:81. [PMID: 24655942 DOI: 10.1186/1748-717X-9-81] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
179 Dai D, Zhao X, Li X, Shu Y, Shen B, Chen X, Chen D, Wang D. Association Between the Microsatellite Instability Status and the Efficacy of Postoperative Adjuvant Chemoradiotherapy in Patients With Gastric Cancer. Front Oncol 2019;9:1452. [PMID: 31970085 DOI: 10.3389/fonc.2019.01452] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
180 Matuschek C, Haussmann J, Bölke E, Tamaskovics B, Djiepmo Njanang FJ, Orth K, Peiper M, Gerber PA, Anooshar B, Kammers K, Budach W. Adjuvant radiochemotherapy vs. chemotherapy alone in gastric cancer: a meta-analysis. Strahlenther Onkol 2019;195:695-706. [PMID: 30796495 DOI: 10.1007/s00066-019-01431-y] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
181 Ho SWT, Tan P. Dissection of gastric cancer heterogeneity for precision oncology. Cancer Sci 2019;110:3405-14. [PMID: 31495054 DOI: 10.1111/cas.14191] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 12.0] [Reference Citation Analysis]
182 Borg D, Hedner C, Nodin B, Larsson A, Johnsson A, Eberhard J, Jirström K. Expression of podocalyxin-like protein is an independent prognostic biomarker in resected esophageal and gastric adenocarcinoma. BMC Clin Pathol 2016;16:13. [PMID: 27478410 DOI: 10.1186/s12907-016-0034-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
183 Agolli L, Nicosia L. Between evidence and new perspectives on the current state of the multimodal approach to gastric cancer: Is there still a role for radiation therapy? World J Gastrointest Oncol. 2018;10:271-281. [PMID: 30254722 DOI: 10.4251/wjgo.v10.i9.271] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
184 Aznab M, Maleksabet D, Khazaei S, Khazaei M, Rezaei M. The Role of Human Epidermal Growth Factor Receptor (HER2/neu) in the Prognosis of Patients with Gastric Cancer. Asian Pac J Cancer Prev 2019;20:1989-94. [PMID: 31350955 DOI: 10.31557/APJCP.2019.20.7.1989] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
185 Aznab M, Ahmadi SM, Khazaei S, Ahmadi SM, Khazaei M, Hamdi H. Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin. Int J Hematol Oncol Stem Cell Res 2020;14:181-7. [PMID: 33024525 DOI: 10.18502/ijhoscr.v14i3.3727] [Reference Citation Analysis]
186 van den Ende T, Ter Veer E, Machiels M, Mali RMA, Abe Nijenhuis FA, de Waal L, Laarman M, Gisbertz SS, Hulshof MCCM, van Oijen MGH, van Laarhoven HWM. The Efficacy and Safety of (Neo)Adjuvant Therapy for Gastric Cancer: A Network Meta-analysis. Cancers (Basel) 2019;11:E80. [PMID: 30641964 DOI: 10.3390/cancers11010080] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
187 Peixoto RD, Lim HJ, Kim H, Abdullah A, Cheung WY. Patterns of surveillance following curative intent therapy for gastroesophageal cancer. J Gastrointest Cancer 2014;45:325-33. [PMID: 24756830 DOI: 10.1007/s12029-014-9601-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
188 Wan Z, Huang Z, Chen L. Survival predictors associated with signet ring cell carcinoma of the esophagus (SRCCE): A population-based retrospective cohort study. PLoS One 2017;12:e0181845. [PMID: 28746362 DOI: 10.1371/journal.pone.0181845] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
189 Agnes A, Estrella JS, Badgwell B. The significance of a nineteenth century definition in the era of genomics: linitis plastica. World J Surg Oncol 2017;15:123. [PMID: 28679451 DOI: 10.1186/s12957-017-1187-3] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
190 Douridas GN, Fountoulakis A, Souglakos J, Gourtsoyianni S, Vini L, Levidou G, Liakakos T, Agalianos C, Dervenis C, Kalogeridi MA, Karavokyros I, Koumarianou A, Kountourakis P, Oikonomopoulos G, Economopoulou P, Sgouros J, Sgouros SN, Stamou K, Triantopoulou C, Zacharoulis D, Gouvas N, Xynos E. Consensus statement of the Hellenic and Cypriot Gastric Cancer Study Group on the diagnosis, staging and management of gastric cancer. Updates Surg 2020;72:1-19. [PMID: 32112342 DOI: 10.1007/s13304-020-00723-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
191 Xu J, Zhu J, Wei Q. Adjuvant Radiochemotherapy vs Chemotherapy Alone for Gastric Cancer: Implications for Target Definition. J Cancer. 2019;10:458-466. [PMID: 30719140 DOI: 10.7150/jca.27335] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
192 Taketa T, Sudo K, Wadhawa R, Blum MM, Ajani JA. Adjuvant therapy in gastric cancer: what is the optimal approach? Curr Oncol Rep. 2013;15:146-151. [PMID: 23355076 DOI: 10.1007/s11912-013-0298-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
193 Chen HS, Hung WH, Ko JL, Hsu PK, Liu CC, Wu SC, Lin CH, Wang BY. Impact of Treatment Modalities on Survival of Patients With Locoregional Esophageal Squamous-Cell Carcinoma in Taiwan. Medicine (Baltimore) 2016;95:e3018. [PMID: 26962818 DOI: 10.1097/MD.0000000000003018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
194 Brunner T. [Despite of the updated analysis of the SWOG-directed Intergroup Study 0116, adjuvant radiochemotherapy is not yet the standard for gastric cancer after curative resection]. Strahlenther Onkol 2012;188:1052-3. [PMID: 23053155 DOI: 10.1007/s00066-012-0218-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
195 Andreollo NA, Drizlionoks E, Tercioti-Junior V, Coelho-Neto JS, Ferrer JAP, Carvalheira JBC, Lopes LR. ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? Arq Bras Cir Dig 2019;32:e1464. [PMID: 31859917 DOI: 10.1590/0102-672020190001e1464] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
196 Oh DY, Bang YJ. Adjuvant and neoadjuvant therapy for gastric cancer. Curr Treat Options Oncol. 2013;14:311-320. [PMID: 23686725 DOI: 10.1007/s11864-013-0238-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
197 Proserpio I, Rausei S, Barzaghi S, Frattini F, Galli F, Iovino D, Rovera F, Boni L, Dionigi G, Pinotti G. Multimodal treatment of gastric cancer. World J Gastrointest Surg. 2014;6:55-58. [PMID: 24829622 DOI: 10.4240/wjgs.v6.i4.55] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
198 Wang X, Jin J, Li YX, Ren H, Fang H, Wang SL, Liu YP, Wang WH, Yu ZH, Song YW, Liu XF. Phase I study of postoperative radiotherapy combined with capecitabine for gastric cancer. World J Gastroenterol 2014;20:1067-73. [PMID: 24574780 DOI: 10.3748/wjg.v20.i4.1067] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
199 Pattison S, Mitchell C, Lade S, Leong T, Busuttil RA, Boussioutas A. Early relapses after adjuvant chemotherapy suggests primary chemoresistance in diffuse gastric cancer. PLoS One 2017;12:e0183891. [PMID: 28922362 DOI: 10.1371/journal.pone.0183891] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
200 Wiedmann MW, Mössner J. New and emerging combination therapies for esophageal cancer. Cancer Manag Res 2013;5:133-46. [PMID: 23869177 DOI: 10.2147/CMAR.S32199] [Cited by in Crossref: 21] [Cited by in F6Publishing: 8] [Article Influence: 2.6] [Reference Citation Analysis]
201 Ronellenfitsch U, Klose J, Kleeff J. Multimodal Therapy of Upper Gastrointestinal Malignancies. Cancers (Basel) 2021;13:793. [PMID: 33672858 DOI: 10.3390/cancers13040793] [Reference Citation Analysis]
202 Schernberg A, Rivin Del Campo E, Rousseau B, Matzinger O, Loi M, Maingon P, Huguet F. Adjuvant chemoradiation for gastric carcinoma: State of the art and perspectives. Clin Transl Radiat Oncol 2018;10:13-22. [PMID: 29928701 DOI: 10.1016/j.ctro.2018.02.005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
203 Guideline Committee of the Korean Gastric Cancer Association (KGCA), Development Working Group & Review Panel. Korean Practice Guideline for Gastric Cancer 2018: an Evidence-based, Multi-disciplinary Approach. J Gastric Cancer 2019;19:1-48. [PMID: 30944757 DOI: 10.5230/jgc.2019.19.e8] [Cited by in Crossref: 103] [Cited by in F6Publishing: 90] [Article Influence: 51.5] [Reference Citation Analysis]
204 Yu JI, Park HC, Lee J, Choi C, Kang WK, Park SH, Kim ST, Sohn TS, Lee JH, An JY, Choi MG, Bae JM, Kim KM, Han H, Kim K, Kim S, Lim DH. Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer. Cancers (Basel) 2020;12:E943. [PMID: 32290335 DOI: 10.3390/cancers12040943] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
205 Wong RK, Jang R, Darling G. Postoperative chemoradiotherapy vs. preoperative chemoradiotherapy for locally advanced (operable) gastric cancer: clarifying the role and technique of radiotherapy. J Gastrointest Oncol. 2015;6:89-107. [PMID: 25642342 DOI: 10.3978/j.issn.2078-6891.2014.089] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
206 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Gastric Signet Ring Cell Carcinoma: Current Management and Future Challenges. Cancer Manag Res 2020;12:7973-81. [PMID: 32943931 DOI: 10.2147/CMAR.S268032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
207 Newton AD, Datta J, Loaiza-Bonilla A, Karakousis GC, Roses RE. Neoadjuvant therapy for gastric cancer: current evidence and future directions. J Gastrointest Oncol. 2015;6:534-543. [PMID: 26487948 DOI: 10.3978/j.issn.2078-6891.2015.047] [Cited by in F6Publishing: 24] [Reference Citation Analysis]
208 Miceli R, Tomasello G, Bregni G, Di Bartolomeo M, Pietrantonio F. Adjuvant chemotherapy for gastric cancer: current evidence and future challenges. World J Gastroenterol. 2014;20:4516-4525. [PMID: 24782604 DOI: 10.3748/wjg.v20.i16.4516] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 19] [Article Influence: 3.3] [Reference Citation Analysis]
209 Barreto SG, Windsor JA. Redefining early gastric cancer. Surg Endosc. 2015;Epub ahead of print. [PMID: 25829068 DOI: 10.1007/s00464-015-4184-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
210 Zhou ML, Wang L, Wang JZ, Yang W, Hu R, Li GC, Sheng WQ, Zhang Z. Validation of the Memorial Sloan Kettering Cancer Center nomogram to predict disease-specific survival in a Chinese gastric cancer population receiving postoperative chemoradiotherapy after an R0 resection. Oncotarget 2016;7:64757-65. [PMID: 27588465 DOI: 10.18632/oncotarget.11665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
211 Kleinberg L, Brock M, Gibson M. Management of Locally Advanced Adenocarcinoma of the Esophagus and Gastroesophageal Junction: Finally a Consensus. Curr Treat Options Oncol 2015;16:35. [PMID: 26112428 DOI: 10.1007/s11864-015-0352-6] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
212 Huang YY, Yang Q, Zhou SW, Wei Y, Chen YX, Xie DR, Zhang B. Postoperative chemoradiotherapy versus postoperative chemotherapy for completely resected gastric cancer with D2 Lymphadenectomy: a meta-analysis. PLoS One. 2013;8:e68939. [PMID: 23874819 DOI: 10.1371/journal.pone.0068939] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 2.6] [Reference Citation Analysis]
213 Yang Q, Wei Y, Chen YX, Zhou SW, Jiang ZM, Xie DR. Indirect comparison showed survival benefit from adjuvant chemoradiotherapy in completely resected gastric cancer with d2 lymphadenectomy. Gastroenterol Res Pract 2013;2013:634929. [PMID: 24194750 DOI: 10.1155/2013/634929] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
214 Chang JS, Choi Y, Shin J, Kim KH, Keum KC, Kim HS, Koom WS, Park EC. Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. Cancer Res Treat 2018;50:118-28. [PMID: 28279066 DOI: 10.4143/crt.2016.575] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
215 Martín-Richard M, Carmona-Bayonas A, Custodio AB, Gallego J, Jiménez-Fonseca P, Reina JJ, Richart P, Rivera F, Alsina M, Sastre J. SEOM clinical guideline for the diagnosis and treatment of gastric cancer (GC) and gastroesophageal junction adenocarcinoma (GEJA) (2019). Clin Transl Oncol 2020;22:236-44. [PMID: 31989475 DOI: 10.1007/s12094-019-02259-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
216 Bautista-Quach MA, Ake CD, Chen M, Wang J. Gastrointestinal lymphomas: Morphology, immunophenotype and molecular features. J Gastrointest Oncol 2012;3:209-25. [PMID: 22943012 DOI: 10.3978/j.issn.2078-6891.2012.024] [Reference Citation Analysis]
217 Schirren R, Reim D, Novotny AR. Adjuvant and/or neoadjuvant therapy for gastric cancer? A perspective review. Ther Adv Med Oncol. 2015;7:39-48. [PMID: 25553082 DOI: 10.1177/1758834014558839] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
218 Gordon MA, Gundacker HM, Benedetti J, Macdonald JS, Baranda JC, Levin WJ, Blanke CD, Elatre W, Weng P, Zhou JY. Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol. 2013;24:1754-1761. [PMID: 23524864 DOI: 10.1093/annonc/mdt106] [Cited by in Crossref: 54] [Cited by in F6Publishing: 47] [Article Influence: 6.8] [Reference Citation Analysis]
219 Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W, Zhang L, Chen H, Wang J, Zhang Y, Zhai Y, Qiu MZ, Yang DJ. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J Exp Clin Cancer Res 2018;37:97. [PMID: 29716622 DOI: 10.1186/s13046-018-0765-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 5.0] [Reference Citation Analysis]
220 Schwarz RE. Current status of management of malignant disease: current management of gastric cancer. J Gastrointest Surg. 2015;19:782-788. [PMID: 25591828 DOI: 10.1007/s11605-014-2707-x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
221 Kilic L, Ordu C, Yildiz I, Sen F, Keskin S, Ciftci R, Pilanci KN. Current adjuvant treatment modalities for gastric cancer: From history to the future. World J Gastrointest Oncol. 2016;8:439-449. [PMID: 27190583 DOI: 10.4251/wjgo.v8.i5.439] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
222 Oblak I, Vidmar MS, Anderluh F, Velenik V, Jeromen A, Hadzic JB. Capecitabine in adjuvant radiochemotherapy for gastric adenocarcinoma. Radiol Oncol. 2014;48:189-196. [PMID: 24991209 DOI: 10.2478/raon-2013-0065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
223 Zhou YJ, Lu XF, Meng JL, Wang XY, Zhang QW, Chen JN, Wang QW, Yan FR, Li XB. Neo-adjuvant radiation therapy provides a survival advantage in T3-T4 nodal positive gastric and gastroesophageal junction adenocarcinoma: a SEER database analysis. BMC Cancer 2021;21:771. [PMID: 34217249 DOI: 10.1186/s12885-021-08534-9] [Reference Citation Analysis]
224 Li Y, Zhu Z, Ma F, Xue L, Tian Y. Improving survival of stage II-III primary gastric signet ring cell carcinoma by adjuvant chemoradiotherapy. Cancer Med 2020;9:6617-28. [PMID: 32744431 DOI: 10.1002/cam4.3342] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
225 Peixoto RD, Rocha-Filho DR, Weschenfelder RF, Rego JFM, Riechelmann R, Coutinho AK, Fernandes GS, Jacome AA, Andrade AC, Murad AM, Mello CAL, Miguel DSCG, Gomes DBD, Racy DJ, Moraes ED, Akaishi EH, Carvalho ES, Mello ES, Filho FM, Coimbra FJF, Capareli FC, Arruda FF, Vieira FMAC, Takeda FR, Cotti GCC, Pereira GLS, Paulo GA, Ribeiro HSC, Lourenco LG, Crosara M, Toneto MG, Oliveira MB, de Lourdes Oliveira M, Begnami MD, Forones NM, Yagi O, Ashton-Prolla P, Aguillar PB, Amaral PCG, Hoff PM, Araujo RLC, Filho RPDP, Gansl RC, Gil RA, Pfiffer TEF, Souza T, Jr UR, Jesus VHF, Jr WLC, Prolla G. Brazilian Group of Gastrointestinal Tumours' consensus guidelines for the management of gastric cancer. Ecancermedicalscience 2020;14:1126. [PMID: 33209117 DOI: 10.3332/ecancer.2020.1126] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
226 Merrett ND. Multimodality treatment of potentially curative gastric cancer: geographical variations and future prospects. World J Gastroenterol. 2014;20:12892-12899. [PMID: 25278686 DOI: 10.3748/wjg.v20.i36.12892] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
227 Huang ZN, Chen QY, Zheng CH, Li P, Xie JW, Wang JB, Lin JX, Lu J, Cao LL, Lin M, Tu RH, Lin JL, Zheng HL, Huang CM. Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer 2018;18:1064. [PMID: 30390644 DOI: 10.1186/s12885-018-4957-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
228 Nishibeppu K, Komatsu S, Ichikawa D, Imamura T, Kosuga T, Okamoto K, Konishi H, Shiozaki A, Fujiwara H, Otsuji E. Venous invasion as a risk factor for recurrence after gastrectomy followed by chemotherapy for stage III gastric cancer. BMC Cancer 2018;18:108. [PMID: 29382310 DOI: 10.1186/s12885-018-4052-z] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
229 Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhlén M, Mardinoglu A, Leandersson K, Jirström K. Expression of PD-L1 and PD-1 in Chemoradiotherapy-Naïve Esophageal and Gastric Adenocarcinoma: Relationship With Mismatch Repair Status and Survival. Front Oncol 2019;9:136. [PMID: 30931254 DOI: 10.3389/fonc.2019.00136] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]